| __timestamp | ADMA Biologics, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 20707000 |
| Thursday, January 1, 2015 | 7015946 | 17831000 |
| Friday, January 1, 2016 | 7688238 | 18047000 |
| Sunday, January 1, 2017 | 6229587 | 11033000 |
| Monday, January 1, 2018 | 3926120 | 13432000 |
| Tuesday, January 1, 2019 | 2343848 | 52072000 |
| Wednesday, January 1, 2020 | 5907013 | 51488000 |
| Friday, January 1, 2021 | 3646060 | 85727000 |
| Saturday, January 1, 2022 | 3613764 | 95518000 |
| Sunday, January 1, 2023 | 3300000 | 125046000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and Geron Corporation have demonstrated contrasting strategies in their R&D investments.
ADMA Biologics, Inc. has shown a steady decline in R&D expenses, starting from a peak in 2014. By 2023, their spending had decreased by approximately 65%, reflecting a strategic shift or potential resource reallocation.
Conversely, Geron Corporation has significantly ramped up its R&D investments, with a staggering 500% increase from 2014 to 2023. This surge underscores their aggressive pursuit of innovation, particularly in the latter half of the decade.
These trends highlight the diverse approaches within the biotech sector, where strategic R&D investments can shape the future of medical advancements.
R&D Insights: How Sanofi and Geron Corporation Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and ADMA Biologics, Inc.
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
R&D Insights: How Bio-Techne Corporation and ADMA Biologics, Inc. Allocate Funds
BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Madrigal Pharmaceuticals, Inc. and ADMA Biologics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
Research and Development Investment: Alkermes plc vs ADMA Biologics, Inc.
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and ADMA Biologics, Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation